Teva Outbids Endo to Secure NuPathe Acquisition
By Heather Cartwright
Pharma Deals Review: Vol 2014 Issue 2 (Table of Contents)
Published: 19 Feb-2014
DOI: 10.3833/pdr.v2014.i2.2010 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Teva Pharmaceutical Industries has outbid Endo Health Solutions with a deal to buy neurology specialist NuPathe for US$144 M upfront in order to gain access to Zecuity® (sumatriptan iontophoretic transdermal system), a prescription migraine patch that was approved by the US FDA in January 2013...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS